Similar articles for PMID: 36288861

Year	Number of Results
2001	2
2007	1
2010	1
2012	1
2014	1
2015	1
2016	1
2017	6
2018	14
2019	17
2020	23
2021	33
2022	34
2023	24
2024	0

1

Letermovir Prophylaxis for CMV Reactivation in Allogeneic Stem Cell Recipients: A Retrospective Single Center Analysis.

Koch K, Osswald L, Miller I, Braitsch K, Götze K, Bassermann F, Herhaus P, Verbeek M. Koch K, et al. Anticancer Res. 2022 Nov;42(11):5431-5441. doi: 10.21873/anticanres.16047. Anticancer Res. 2022. PMID: 36288861

2

Letermovir Discontinuation at Day 100 After Allogeneic Stem Cell Transplant Is Associated With Increased CMV-Related Mortality.

Liu LW, Yn A, Gao F, Olson M, Crain M, Abboud R, Westervelt P, Abboud C, Vij R, Stockerl-Goldstein K, Pusic I, Cashen AF, Schroeder MA. Liu LW, et al. Transplant Cell Ther. 2022 Aug;28(8):510.e1-510.e9. doi: 10.1016/j.jtct.2022.05.020. Epub 2022 May 20. Transplant Cell Ther. 2022. PMID: 35598841 Free article.

3

Real world experience: Examining outcomes using letermovir for CMV prophylaxis in high-risk allogeneic hematopoietic stem cell patients in the setting of using T-cell depletion as GVHD prophylaxis.

Dwabe S, Hsiao M, Ali A, Rodman J, Savitala-Damerla L, Nazaretyan S, Kimberly Schiff NP, Tam E, Ladha A, Woan K, Chaudhary P, Yaghmour G. Dwabe S, et al. Transpl Immunol. 2023 Feb;76:101769. doi: 10.1016/j.trim.2022.101769. Epub 2022 Dec 2. Transpl Immunol. 2023. PMID: 36464218

4

Letermovir for primary and secondary cytomegalovirus prevention in allogeneic hematopoietic cell transplant recipients: Real-world experience.

Lin A, Maloy M, Su Y, Bhatt V, DeRespiris L, Griffin M, Lau C, Proli A, Barker J, Shaffer B, Giralt SA, Jakubowski AA, Papadopoulos EB, Papanicolaou GA, Seo SK, Perales MA. Lin A, et al. Transpl Infect Dis. 2019 Dec;21(6):e13187. doi: 10.1111/tid.13187. Epub 2019 Oct 21. Transpl Infect Dis. 2019. PMID: 31585500 Free PMC article.

5

Risk factor analysis for cytomegalovirus reactivation under prophylaxis with letermovir after allogeneic hematopoietic stem cell transplantation.

Mizuno K, Sakurai M, Kato J, Yamaguchi K, Abe R, Koda Y, Kataoka K, Mori T. Mizuno K, et al. Transpl Infect Dis. 2022 Dec;24(6):e13904. doi: 10.1111/tid.13904. Epub 2022 Jul 28. Transpl Infect Dis. 2022. PMID: 35870130

6

Clinical "real-world" experience with letermovir for prevention of cytomegalovirus infection in allogeneic hematopoietic cell transplant recipients.

Anderson A, Raja M, Vazquez N, Morris M, Komanduri K, Camargo J. Anderson A, et al. Clin Transplant. 2020 Jul;34(7):e13866. doi: 10.1111/ctr.13866. Epub 2020 Apr 19. Clin Transplant. 2020. PMID: 32242979

7

Letermovir Prophylaxis for Cytomegalovirus Infection in Children After Hematopoietic Cell Transplantation.

Richert-Przygonska M, Jaremek K, Debski R, Konieczek J, Lecka M, Dziedzic M, Bogiel T, Styczynski J, Czyzewski K. Richert-Przygonska M, et al. Anticancer Res. 2022 Jul;42(7):3607-3612. doi: 10.21873/anticanres.15848. Anticancer Res. 2022. PMID: 35790275

8

Prophylactic letermovir decreases cytomegalovirus reactivation after stem cell transplantation: a single-center real-world evidence study.

Serio B, Giudice V, Guariglia R, Fontana R, Pezzullo L, Martorelli MC, Ferrara I, Mettivier L, D'Addona M, Vaccaro E, Langella M, Selleri C. Serio B, et al. Infez Med. 2021 Mar 1;29(1):102-113. Infez Med. 2021. PMID: 33664179 Free article.

9

Cytomegalovirus breakthrough and resistance during letermovir prophylaxis.

Perchetti GA, Biernacki MA, Xie H, Castor J, Joncas-Schronce L, Ueda Oshima M, Kim Y, Jerome KR, Sandmaier BM, Martin PJ, Boeckh M, Greninger AL, Zamora D. Perchetti GA, et al. Bone Marrow Transplant. 2023 Apr;58(4):430-436. doi: 10.1038/s41409-023-01920-w. Epub 2023 Jan 24. Bone Marrow Transplant. 2023. PMID: 36693927

10

Refractory and Resistant Cytomegalovirus After Hematopoietic Cell Transplant in the Letermovir Primary Prophylaxis Era.

Sassine J, Khawaja F, Shigle TL, Handy V, Foolad F, Aitken SL, Jiang Y, Champlin R, Shpall E, Rezvani K, Ariza-Heredia EJ, Chemaly RF. Sassine J, et al. Clin Infect Dis. 2021 Oct 20;73(8):1346-1354. doi: 10.1093/cid/ciab298. Clin Infect Dis. 2021. PMID: 33830182 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

131 results

Results by year